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INTRODUCTION
Discovered almost a century ago [1] , insulin is widely known for its essential role in reducing blood glucose levels through the stimulation of glucose uptake by muscle, liver and adipose tissues. Pancreatic beta cells secrete insulin, a process that is crucial for determining blood glucose levels. Beta cells detect extracellular glucose concentrations through the glucose transporter GLUT2. Importantly, unlike the glucose transporters in insulin-sensitive tissues (predominantly GLUT4), GLUT2 is not regulated by insulin, thus the drop in blood glucose level due to the action of GLUT4 triggers a negative feedback mechanism suppressing insulin secretion through GLUT2 positioned on beta cells. Type 1 diabetes mellitus is a consequence of the partial or complete loss of beta cells, which leads to impaired insulin secretion and uncontrolled blood glucose levels (hypoinsulinaemic hyperglycemia). In type 2 diabetes, insulin levels are indirectly disturbed. Insufficient insulin action on receptors in insulinsensitive tissues allows blood glucose levels to rise, leading to enhanced insulin release by beta cells. This insulin release is initially capable of restoring normal blood glucose concentrations (hyperinsulinaemic euglycemia). When beta cells reach their maximal insulinproducing capacity and are no longer able to maintain normal blood glucose, the state of hyperinsulinaemic hyperglycemia known as type 2 diabetes arises.
The function of insulin, however, is not restricted to peripheral organs. In the brain, the insulin-independent GLUT1 and GLUT3 are predominantly responsible for glucose uptake in glial cells and neurons, respectively [2] . Accordingly, brain metabolism has been considered insulin independent for decades, but the discovery of insulin receptors in the brain [3] now indicates that the cerebral functions of insulin are more complex. Insulin receptors expressed in the brain are similar to those found in the periphery [4] , with the highest expression detected in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus and cerebellum [3] . Insulin receptor levels are higher in neurons than in glial cells [5] .
Importantly, there are similarities in the periphery and the brain in the major signal transduction pathways linked to the insulin receptor. The phosphoinositide-3 kinase (PI3)/Akt and Ras/mitogen-activated protein kinase (MAPK) routes crucial to peripheral glucose, lipid and protein metabolism [6] are also essential in the mechanism of insulin action in the brain [4, 7] .
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External insulin reaches the brain
As outlined above, a normal supply of insulin in the brain appears to be crucial for neural function, including metabolism, and, consequently, dynamic or persistent alterations in insulin-dependent mechanisms could contribute to pathological processes. The sources of insulin found in the brain are not completely clear. It is generally accepted that insulin synthesised by pancreatic beta cells is delivered to the brain [8] [9] [10] [11] [12] [13] , but an accurate picture of this process is missing (Fig. 1) [14] . Pancreatic insulin circulating in the plasma has two ways into the interstitial fluid immediately surrounding neurons and glial cells of the brain.
The first pathway delivers relatively small amounts of plasma insulin through the choroid plexus to the cerebrospinal fluid. Plasma concentrations of insulin are an order of magnitude higher compared with those measured in the cerebrospinal fluid [15, 16] .
Interestingly, this difference is increased in obesity [17] , despite the higher plasma insulin concentrations in obese individuals. This process is saturable [13, 18] , but it is not clear whether saturation is caused by the potential involvement of insulin receptors of the choroid plexus or by the suspected contribution of megalin, a transporter known to mediate leptin transport across the choroid plexus and to be involved in insulin transport [19] in the epithelial cells of renal tubules [20] .
The second pathway takes insulin from plasma into the endothelial cells of the brain microvasculature. Based on experiments showing that aortic endothelial cells outside the brain are able to concentrate insulin [21] , the second pathway is hypothesised to transport the bulk of peripheral insulin to the brain. Mechanisms of transendothelial insulin transport in the brain have not been directly studied to date, but one can speculate that a vesicular trafficking process, beginning with insulin binding to its receptor followed by the involvement of caveolae and promoted by NO signalling [21] [22] [23] [24] , could be involved according to experiments with peripheral endothelia. The two pathways join at the Virchow-Robin space surrounded by endothelial cells, astrocytic endfeet and pericytes. Peripheral insulin then passes the line of astrocytic endfeet, an effective filter and limiter of movement speed for larger molecules [25] , before reaching the interstitial space around neurons and glia. Absolute insulin concentrations are difficult to measure reliably in the interstitial space of the brain, but the relative changes detected in response to food intake were independent of plasma insulin concentration [26, 27] , raising the possibility that pancreas-independent local insulin synthesis occurs in the brain [10] .
The speed of pancreatic insulin transport into the cerebrospinal fluid and then to the interstitial space of the brain is orders of magnitude slower than the operating speed of neural 7 networks estimated according to the lowest frequency of brain oscillations. Insulin levels in the cerebrospinal fluid remain below fasting levels in response to several hours of peripheral hyperinsulinaemic euglycaemic clamping [16, 18] and, moreover, fasting insulin levels in the cerebrospinal fluid (~7 pmol/l) [28] are insufficient for signal transduction through insulin receptors. Even if insulin concentrations in the cerebrospinal fluid are elevated to effective levels, it is estimated that the slow circulation of cerebrospinal fluid limits insulin delivery to the interstitial space of the brain at a rate of ~1/600 of that to skeletal muscle and at < 1/30,000 of that to the liver [14] . Alternatively, insulin might move directly from the plasma through the blood-brain barrier to the Virchow-Robin space and the interstitial fluid. Studies examining the involvement of this route measured the tissue content of radiolabelled insulin in brain regions [29] , which did not allow the insulin concentration in the interstitial fluid to be determined. To date, estimations of the speed by which insulin moves across the bloodbrain barrier are limited by brain microvessels binding insulin with high affinity without significant insulin degradation [30] . Nevertheless, insulin finds its way from the plasma to the immediate vicinity of neurons, but equilibration with the interstitial space in the brain is achieved at timescales consistent with long-term homeostatic regulation outside the frequency range (~0.1-200 Hz ) of changes in membrane potential in neural networks.
The limited speed by which external insulin is distributed is also a factor to consider when delivering insulin to the brain intranasally [28] . This process has gained particular relevance following encouraging reports [31] and clinical trials [32] that provide evidence for cognitive improvements with daily intranasal insulin administration in patients with mild cognitive impairment or mild to moderate Alzheimer's disease. Levels of insulin are reduced in Alzheimer's disease [33, 34] , and intranasally applied insulin raises concentrations in the cerebrospinal fluid within 10 min of application, with maximal levels achieved after 30 min, while plasma insulin and glucose levels remain unaffected [28] . How intranasal insulin reaches the brain remains mechanistically unclear [35] , but the process can be stimulated by inhibiting protein kinase C [36] . A different strategy for increasing insulin concentrations in key areas affected by Alzheimer's disease, such as the hippocampus and neocortex, would be to boost insulin release from neurons or neuronal progenitors expressing insulin locally.
Local insulin synthesis in the brain
Whether insulin is produced locally in the central nervous system is not a trivial question to answer. Initial studies on the subject suggested that immunoreactive insulin is present in the rat brain in concentrations 10 to 100 times higher than in the plasma [37] , but this was 8 challenged by subsequent findings [38] , leading to the conclusion that 'little or no insulin is produced in the brain' [39] . The heart of the problem is that experiments must be able to differentiate between insulin of pancreatic origin and insulin synthesised locally. Anti-insulin antibodies recognise the same epitopes on pancreas-and brain-derived insulin, thus methods such as anti-insulin immunocytochemistry or radioimmunoassay capable of detecting insulin in small amounts are not adequate. Increasing the resolution to allow cellular or subcellular localisation of anti-insulin immunoreaction signals is of little help as receptor-bound and internalised insulin pools are degraded or recycled to the plasma membrane at intracellular locations that potentially overlap with those of locally synthesised peptide [40] .
Immunoreactions detecting peptides involved in the different steps of insulin synthesis might overcome these limitations. Indeed, C-peptide, an integral part of proinsulin, was localised to the same neurons as insulin [41] [42] [43] , and proinsulin-like immunoreactivity was documented in samples derived from the central nervous system [44] , arguing for local synthesis in the brain.
Another strategy for detecting insulin production in the brain is to search for the mRNA of insulin-coding genes: Ins1 and Ins2 in mice; Ins2 in rat; and INS in humans. A pioneering RT-PCR study detected widespread Ins2 expression in the rat brain throughout development [45] and the same laboratory confirmed it in rabbit, showing Ins2 expression in neurons of the hippocampus and olfactory bulb [46] . More recently, hippocampal granule cells from adult rats and neuronal progenitor cells derived from the hippocampus or olfactory bulb were also found to express insulin mRNAs [43] . Furthermore, expression of Ins2, but not Ins1, was found in cortical and subcortical areas of the mouse brain [47, 48] and INS mRNA expression characterised human samples of the hippocampus, amygdala and temporal lobe in addition to the olfactory bulb, cerebellar and pontine regions [48] . Recently developed methods to precisely quantify mRNA copy numbers in single neurons [49] have provided an effective tool for determining Ins2 levels in several cell types and astrocytes in the cerebral cortex.
Glucagon-like peptide 1 and the brain
Glucagon-like peptide 1 (GLP-1), produced by L cells of the intestine, is important in blood glucose homeostasis, acting through several classic mechanisms including the inhibition of gastric emptying, suppression of pancreatic glucagon secretion and enhancement of insulin release in the pancreas [50] . Insulin delivered intranasally to the brain is therapeutically promising against mild cognitive impairment and Alzheimer's disease [32] , and the GLP-1 analogues used in diabetes treatment have preventive effects in the early stage of Alzheimer's disease development [59, 60] , Parkinson's disease [59, 61] and traumatic brain injury [62, 63] . We suggest that novel therapeutic strategies might include modulation of neural insulin production in the brain by GLP-1 agonists in order to counteract diabetes, obesity and neurodegenerative diseases.
Therefore, it is of potential importance to determine whether GLP-1 of intestinal or neural origin or therapeutically applied GLP-1 receptor agonists find targets on neurons capable of insulin production. In the current study, we tested whether interneurons of the rat neocortex have the molecular components to be involved in GLP-1 signalling.
MATERIALS AND METHODS
Animals
All procedures were performed with the approval of the University of Szeged (no. 
Electrophysiology and imaging
Animals were anaesthetized by intraperitoneal injection of ketamine (30 mg/kg) and xylazine (10 mg/kg) and, following checking of the cessation of pain reflexes and decapitation, coronal slices (350 µm) were prepared from the somatosensory cortex. Animals used for this study also provided brain slices for other projects performed in parallel in the laboratory. Slice preparation and recordings were performed as previously described [49] . Recordings were Pre-treatment with exendin-3(9-39) (1 µmol/l, Tocris, Bristol, UK) was applied for 4 h prior to recording sessions under hyperglycaemic (10 mmol/l glucose) conditions. Voltage clamp protocols were applied according to [64] . Detection of spontaneous EPSCs were performed with NeuroMatic functions for Igor Pro (Wavemetrics). In our low chloride recording conditions, reversal potential of unitary inhibitory postsynaptic potential was -73.3 ± 3mV thus, separation of GABAergic currents was based on polarity. After Gaussian filtering, EPSC events were detected with the threshold detection algorithm as described by Kudoh and Taguchi (2002) [65] and events were reviewed after automatic detection. Threshold was set to (wt/vol.) uranyl acetate and dehydrated using an ascending series of ethanol. Sections were infiltrated with epoxy resin (Durcupan; Sigma-Aldrich) overnight and embedded on glass slides. Three-dimensional light microscopic reconstructions were carried out using the Neurolucida system (MicroBrightField, Williston, VT, USA) with a 100 objective.
Single-cell reverse transcription, QRT-PCR and digital PCR
At the end of electrophysiological recordings, the intracellular content was aspirated into recording pipettes by applying a gentle negative pressure while maintaining a tight seal [49] .
The pipettes were then delicately removed to allow outside-out patch formation and the content of the pipettes (~1. nuclease-free water) in MyGenie 32 Thermal Block (Bioneer) using protocols as described [49] . We repeated QRT-PCRs (traditional and digital) amplifying both the control gene Rps18 Processing of the OpenArray slide, cycling in the OpenArray NT cycler and data analysis were performed as previously described [49] . For our digital PCR protocol for amplification, reactions with C t confidence values < 100 were considered not different from background noise and were excluded from the dataset. In addition, reactions with C t values < 23 were considered primer dimers and those > 33 were considered false reactions originated from nontemplate amplifications and were excluded from the dataset.
Sequencing
We sequenced 4 individual PCR products from 4 individual neurogliaform cells using capillary electrophoresis sequencing on 3500 Genetic Analyzer (Life Technologies). After purification of the products, we used 4 different sequencing primers using the following 
Radioimmunoassay. Insulin extraction of cells was performed in the cold by the acid-ethanol
technique. Radioimmunoassay (Sensitive Rat Insulin RIA kit, Millipore) was used to determine insulin contents with a sensitivity of 2 pg/tube. BCA protein assay kit (Pierce) was used for detecting total protein content.
Statistical analysis
Data are given as means ± SD. Datasets were statistically compared using one-way ANOVA or the Kruskal-Wallis or Wilcoxon tests. The Mann-Whitney U test was used for electrophysiological measurements with SPSS software (IBM, Armonk, NY, USA).
Differences were accepted as significant if p < 0.05. Randomisation of samples and blinding was not carried out for outcome assessment.
RESULTS
Cell type dependent insulin mRNA expression in the cerebral cortex
We tested whether different neocortical neuron types, all of them identified by whole cell recordings and subsequent light microscopic assessment ( Fig. 2A) , express the mRNA of the Ins2 gene encoding preproinsulin in the rat [66] . After electrophysiological and anatomical identification of cell types based on characterization of membrane and firing properties ( (Fig. 2C) . In high extracellular glucose concentration (10 mmol/l) which is standard for brain slice electrophysiology experiments, individual neurogliaform cells (n = 10) contained higher numbers of Ins2 mRNAs (30 ± 13) compared to pyramidal (7 ± 2, n = 6) and fast spiking cells (5 ± 3, n = 5, p < 0.002, Kruskal-Wallis test). As a functional control, we lowered the glucose concentration to levels close to what was found in the brain during normoglycemia (2.4 mmol/l) and hypoglycemia (0.5 mmol/l) [67] and this decreased the number of Ins2 mRNA molecules in single neurogliaform cells to 14 ± 3 (n = 5, p < 0.008, Kruskal-Wallis test) and further to 7 ± 4 per cell (n = 5, p < 0.04). In contrast, copy numbers of Rps18 mRNAs coding the homeostatic ribosomal protein S18 [66] were similar in neurogliaform (n = 16, 65 ± 18), pyramidal (n = 14, 63 ± 26) and fast spiking cells (n = 15, 61 ± 25) regardless of external glucose concentrations. In further control experiments, we determined the number of Rps18 (26 ± 6) and Ins2 (1 ± 0.8) mRNAs in glial cells (n = 5 and 4, respectively) showing that our data on mRNA copy numbers exclude DNA contamination which might arise in small cells. The copy number of Rps18 (p < 0.01) and Ins2 (p < 0.04) mRNAs in glial cells was less than in either of the three neuron types we tested (Fig. 2C ). In addition, we repeated conventional and digital PCRs amplifying both Rps18 and Ins2 without reverse transcriptase reaction and found no amplification and no PCR products meaning that genomic DNA amplification was negligible (Fig. 2C ).
Insulin release from identified neurons
An increase in extracellular glucose level might act as a physiological trigger in releasing insulin from neurogliaform cells containing Ins2 mRNAs. In order to test this hypothesis, we first searched for electrophysiologically measurable effects of external insulin in brain slices and administered insulin in the bath in concentrations (100 nmol/l) taking into account extraand intracellular space ratios (0.18) and the ~140 µm diffusion into the slice pushing local concentrations down to a few nanomolar at our recording sites [37, 68] . 
Mechanisms leading to insulin-like effects of neurogliaform cells
Following previous studies showing that the ATP-sensitive potassium (K ATP ) channel blocker glibenclamide promotes both insulin expression and release [71] , we confirmed the presence of K ATP channels in neurogliaform cells using protocols established for cortical interneurons [72] . Relative to control conditions having a partially suppressed activity of K ATP channels due hypoglycaema (0.5 mmol/l) in the external solution [71] , glibenclamide (20 μM) in the bath produced a current with current-voltage characteristics of K ATP channels in neurogliaform cells (n = 8) with a reversal potential (-96.6 ± 2.9 mV) close to the potassium equilibrium potential (Fig. 4A) . mmol/l, determined as the hypoglycaemic external glucose concentration in the rat brain [67] .
Differential interference contrast microscopy was used to select putative interneurons based on perisomatic morphology, and the identity of neurogliaform cells was first confirmed according to their late-spiking firing characteristics in response to depolarising current pulses ( Fig. 5A-D) . The use of biocytin in the patch-clamp recording pipettes allowed us to recover the morphology of the recorded cells, and the identity of each neurogliaform cell included in this study (n = 87) was additionally confirmed by post hoc anatomical assessment of axonal morphology ( Fig. 5A-D) . Quantitative morphological analysis was beyond the scope of this study; however, an extremely dense axonal arborisation with small and frequently spaced boutons, the hallmark of neurogliaform cells [73] , could be readily observed in samples recorded and biocytin filled in hyper-and hypoglycaemic conditions. In addition, no somatodendritic differences seemed to emerge between the two experimental groups and no morphological features considered pathological were observed.
We compared the basic electrophysiological properties of neurogliaform cells recorded in 10 mmol/l (n = 10) and 0.5 mmol/l (n = 10) external glucose concentrations (Fig. 5E-M) .
Hyper-vs hypoglycaemic conditions had no significant effect on the resting membrane Fig. 6A ) with the homeostatic gene S18 (also known as Rps18) as a reference. Moreover, we compared copy numbers of Glp1r mRNA in neurogliaform cells (n = 5) in hypoglycemia, and found that copy numbers in hyperglycemia exceeded those in hypogycaemia by 9.6 times when normalised to copy numbers of the homeostatic S18 gene (0.0457 ± 0.0427 and 0.0048 ± 0.0066; p < 0.008, Mann-Whitney U test; Fig. 6A ).
We next asked whether GLP-1 receptors and insulin can be co-detected in individual neurogliaform cells (Fig. 6B) . Our single-cell digital PCR method allows the exact measurement of mRNA copy numbers of no more than two genes, thus we replaced the The co-expression of GLP-1 receptors and insulin in neurogliaform cells gives rise to a potentially broader molecular similarity between pancreatic beta cells and neurogliaform neurons of the cerebral cortex. Indeed, the developmental lineage for pancreatic endocrine cells and neurons has been suggested to be related [75] . Following these ideas, our final series of experiments using single-cell digital PCR on identified neurogliaform cells (n = 5) revealed the expression of transcription factors important in beta cell development (Pdx1, Isl1 and Mafb copy numbers relative to S18: 0.0755 ± 0.0395, 0.0218 ± 0.0057 and 0.0279 ± 0.0254, respectively; Fig. 7 ) [76, 77] . In addition, we detected a significantly lower normalised mRNA copy numbers of Pdx1 and Isl1 in hypoglycemia (n = 5; 0.0073 ± 0.0163, 0.0051 ± 0.0072; p < 0.037 and p < 0.016 vs hyperglycemia, respectively, Mann-Whitney U test; Fig.   7 ).
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DISCUSSION
Insulin expression and release by interneurons of the cerebral cortex
According to a textbook method for identifying a neurotransmitter, neurogliaform cells mimicked the reversible effect of externally added insulin by releasing a substance we identified as insulin based on the same specific receptor antagonist. It remains to be established how and when peptides in general are being released from interneurons.
Neuropeptide release was shown to depend on dendritic Ca 2+ entry, but does not necessarily require somatic action potentials [78] . This suggests that GABAergic cells can contribute to local insulin release in conditions when pancreatic insulin supply temporarily or permanently does not match demand, e.g. the actual extracellular glucose availability.
Insulin action in the brain
Given the parallel expression of insulin-activated PI3/Akt and Ras/MAPK pathways in the periphery and the brain, a logical question is whether insulin-mediated effects on neurons involve metabolic regulation. Insulin receptors and the insulin-sensitive glucose transporter GLUT4 have been shown to co-localise on neurons [79] , and cellular mechanisms supporting neuronal metabolic functions of insulin involve translocation of GLUT4 to the cell surface [80] , so providing an alternative to insulin-independent glucose uptake through GLUT3. The insulin dependence of brain metabolism at the neural network level has also been revisited by a number of human in vivo studies [81] [82] [83] , which suggest that insulin can effectively stimulate glucose uptake in the medial temporal lobe, especially during periods of intensive neuronal activity [84] . Moreover, a rapid increase in local glycolysis following insulin administration was found in the hippocampus and was suppressed in type 2 diabetes [85] .
However, glucose levels drop significantly in the extracellular space during intense cognitive operations and might not be rate-limiting for the metabolic supply of microcircuits because of astrocytic metabolic routes [86] . A consensus on neuronal glucose metabolism in relation to insulin is of particular interest for two reasons. First, neuronal ensembles in the hippocampus and the neocortex are engaged in increased high-frequency epochs of firing during memory formation or cognitive tasks and the extra metabolic demand created by intensive action potential generation might be met by alternative routes of supply. An unorthodox pathway of glucose supply during cognitive surges in energy demand was suggested by Emmanuel et al [84] , who proposed that non-insulin-dependent GLUT1 and GLUT3 transport is sufficient for resting brain activity, while sustained cognitive activity induces the addition of insulinsignalled GLUT4 transport. Second, unlike in other organs, glucose is central for the energy metabolism of the brain and temporary or sustained changes in glucose supply could be crucial in differentiating the normal and pathological functions of neural circuits. Cognitive deficits are associated with insulin resistance and diabetes [87, 88] and impaired insulindependent mechanisms for glucose uptake during tasks requiring extra supply might lead to deficient energy metabolism [84] . Along the same vein, 'type 3 diabetes' was suggested as an alternative term for Alzheimer's disease [34] , based on observations showing reduced insulin expression and signalling mechanisms in the sporadic form of the disease [89] .
In addition to the involvement in neuronal metabolism, the classic PI3/Akt and Ras/MAPK insulin-activated pathways are also important in neuron-specific cellular functions, such as the development of neuronal dendritic arbors [90] and the maintenance of excitatory synapses [91, 92] . These functions are crucial in regulating cellular processes of learning and memory and lead to long-term potentiation (LTP) or long-term depression (LTD) of synaptic efficacy through the removal of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors from postsynaptic specialisations for LTD [91, 92] and through shifting the stimulation frequency-response function for LTP [93] . Corroborating these results, a deficit of LTP is observed in models of type 1 diabetes, but results from experiments using type 2 diabetes model systems are not unequivocal [80] . Insulin is instrumental in modulating inhibitory mechanisms by moving additional -aminobutyric acid (GABA) receptors to inhibitory synapses [94] and extrasynaptic regions of the plasma membrane [95] , providing mechanisms synergistic with the LTD induction detailed above for shifting the balance away from excitation in neural networks.
Neurogliaform interneurons, capable of releasing insulin in cortical microcircuits, are also GABAergic [96] and use GABA for volume transmission of widespread inhibition [73] , thus these cells are ideally suited to synchronise the local actions of insulin and GABA. It is
22 not yet known which combination of neural afferents elicit insulin release from neurogliaform cells. However, it is reasonable to assume that strong excitatory inputs might contribute to the intracellular Ca 2+ accumulation required for peptide release. One can speculate that insulin release could be synchronised to elevated overall activity in networks around neurogliaform neurons. This way transient local energy demand could be met by insulin release-driven additional glucose transport through insulin-dependent GLUT4, as suggested for epochs of intense hippocampal or cortical activity during cognitive processing [84] . At the same time, the overall excitation-suppressing activity of insulin released from neurogliaform cells is likely to be coupled with the synchronous release and inhibitory action of GABA from neurogliaform cells, which might curtail energy demand.
At the neuronal network level, insulin is an effective neuromodulatory peptide with an array of effects including control of food intake and body weight, regulation of the reproductive or hypothalamic-pituitary-gonadal axis, influencing neuronal survival and modulation of memory and cognitive processes [9] [10] [11] [12] . Apart from the classic cellular signalling pathways, insulin also acts through alternative mechanisms in neurons. Insulin directly opens neuronal ATP-gated potassium (K ATP ) channels, resulting in suppressed firing [97] , and this signalling route was suggested as a mechanism for modulating hippocampal memory performance [98] . Moreover, the action of insulin on neurons might interact with glucocorticoid signalling through opposite modulation of hippocampal GLUT4 [99] and by additional mechanisms expertly reviewed previously [80, 86] .
GLP-1 receptor expression in insulin expressing neurons
Our [108, 109] . Synergistically with the basic helix-loophelix transcription factor BETA2, ISL1 activates the insulin promoter in beta cells [110] and promotes pancreatic islet cell proliferation [111] , and is required for the differentiation of interneurons in the spinal cord [112] . The role of Mafa and Mafb genes is crucial in beta cells during development (Mafb) and adulthood (Mafa in mice and MAFA and MAFB in humans) [113] and our results in neurogliaform cells confirm the widespread expression of MAFB reported earlier in developing and differentiated neocortical interneurons [114] . Our results suggest that insulin and GLP-1 receptor-expressing neurogliaform interneurons of the cerebral cortex partially possess the transcription toolkit known to be instrumental in the development of insulin-synthesising pancreatic beta cells.
Neuron-derived insulin-based therapy
The effect of glibenclamide in triggering neuronal release of insulin also suggests that the delivery of substances known to enhance insulin release from pancreatic beta cells to the brain suggest that the prefrontal cortex is crucial in the inhibitory control of food intake [115] [116] [117] and human brain-slice experiments showing that neurogliaform cells provide widespread inhibition in prefrontal microcircuits [118] . The expression of GLP-1 receptors on insulinreleasing neurogliaform neurons of the prefrontal cortex provides mechanistic support for this process. Selective involvement of GABAergic interneuron subpopulations is likely in neurodegenerative diseases [119] . Given that GLP-1 receptor agonists promise therapeutic effectiveness against neurodegeneration in models of Alzheimer's, Huntington's and
Parkinson's diseases [120, 121] and a scenario of GLP-1 receptor-mediated insulin synthesis in the brain could be extended to therapy for these diseases.
The evidence for insulin synthesis in the brain raises the question of whether brainderived insulin could be used to replace peripheral insulin in type 1 diabetes. Insulin synthesised in the brain is unlikely to cross the blood-brain barrier in the brain-to-blood direction in the quantity required for euglycaemic control of plasma glucose concentrations [11] ; intranasal insulin delivery fails to increase plasma insulin levels significantly [28] . An alternative approach might use autologous grafts of insulin-expressing neurons or neural progenitor cells as a potential replacement for lost pancreatic beta cells. Such neuron-or neural stem cell-based therapy of diabetes is suggested following the spectacular results of Kuwabara et al [43] that raised the possibility of neural stem cells isolated from the adult brain functionally replacing beta cells in diabetic patients [122, 123] . The suggested workflow for autologous neural stem cell-based therapy for diabetes is, critically, based on the suggestion that insulin-expressing neural stem cells of the dentate gyrus or the olfactory bulb might find similar molecular niches for their survival and insulin-expressing ability in the brain as well as in the pancreas, and that this might involve Wnt3 and neurogenic differentiation factor 1 (NeuroD) [43, 123] . 
SUMMARY AND CONCLUSION
The action of insulin is not restricted to peripheral organs. Insulin receptors and signal 
